156 related articles for article (PubMed ID: 35770978)
21.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
22. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
23. Value of Dynamic
Kupik O; Tuncel M; Özgen Kıratlı P; Akpınar MG; Altundağ K; Başaran Demirkazık F; Erbaş B
Mol Imaging Radionucl Ther; 2023 Jun; 32(2):94-102. PubMed ID: 37337702
[TBL] [Abstract][Full Text] [Related]
24. Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Pathologic Response to Preoperative Chemoradiotherapy and Prognosis in Patients With Locally Advanced Rectal Cancer.
Koo PJ; Kim SJ; Chang S; Kwak JJ
Clin Colorectal Cancer; 2016 Dec; 15(4):e213-e219. PubMed ID: 27316919
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of
Han S; Choi JY
Breast Cancer Res; 2020 Oct; 22(1):119. PubMed ID: 33129348
[TBL] [Abstract][Full Text] [Related]
26. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
27. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
28. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer.
Kaya S; Aktas B; Tanrikulu Sismek E; Akif Ozturk M; Dede F; Kaya H; Ugurlu U; Ozgen Z; Koca S; Halil S; Hasanov R; Alan O; Akgul Babacan N; Ercelep O; Dane F; Gumus M; Yumuk F
J BUON; 2017; 22(5):1191-1198. PubMed ID: 29135102
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of metabolic response with
Segreto S; Fonti R; Ottaviano M; Pellegrino S; Pace L; Damiano V; Palmieri G; Del Vecchio S
Cancer Imaging; 2017 Mar; 17(1):10. PubMed ID: 28264726
[TBL] [Abstract][Full Text] [Related]
30. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
31. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
32. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
33. Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Ohsawa M; Hirohata R; Kitasaki N; Okada M
Anticancer Res; 2022 Dec; 42(12):6037-6045. PubMed ID: 36456150
[TBL] [Abstract][Full Text] [Related]
34. MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Aiba T; Uehara K; Nihashi T; Tsuzuki T; Yatsuya H; Yoshioka Y; Kato K; Nagino M
Ann Surg Oncol; 2014 Jun; 21(6):1801-8. PubMed ID: 24531702
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Axillary Lymph Node Texture Parameters Measured by Pretreatment
Hwang JP; Choi JY; Choi JH; Cho YS; Hur SM; Kim Z; Lim CW; Seo S; Moon JE; Woo SK; Park JM
Diagnostics (Basel); 2022 Sep; 12(10):. PubMed ID: 36291974
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy.
Bae SJ; Ahn SG; Ji JH; Chu CH; Kim D; Lee J; Park S; Cha C; Jeong J
J Breast Cancer; 2022 Dec; 25(6):485-499. PubMed ID: 36479600
[TBL] [Abstract][Full Text] [Related]
37. The prognostic role of baseline
Can C; Akdeniz N; Kömek H; Gündoğan C; Urakçı Z; Işıkdoğan A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Aug; ():. PubMed ID: 34353770
[TBL] [Abstract][Full Text] [Related]
38. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
[TBL] [Abstract][Full Text] [Related]
39. Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy.
Ishiba T; Nakagawa T; Sato T; Nagahara M; Oda G; Sugimoto H; Kasahara M; Hosoya T; Kubota K; Fujioka T; Danenberg P; Danenberg K; Uetake H
Springerplus; 2015; 4():817. PubMed ID: 26722637
[TBL] [Abstract][Full Text] [Related]
40. Percentage change of primary tumor on 18F-FDG PET/CT as a prognostic factor for invasive ductal breast cancer with axillary lymph node metastasis: Comparison with MRI.
Yoo J; Kim BS; Chung J; Yoon HJ
Medicine (Baltimore); 2017 Aug; 96(31):e7657. PubMed ID: 28767583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
